argenx SE (NASDAQ:ARGX) Stock Holdings Raised by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lifted its stake in shares of argenx SE (NASDAQ:ARGX) by 11.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,255 shares of the company’s stock after purchasing an additional 339 shares during the period. Oppenheimer Asset Management Inc.’s holdings in argenx were worth $1,400,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD lifted its holdings in argenx by 49.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after buying an additional 1,830,651 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in argenx by 12.2% during the fourth quarter. Artisan Partners Limited Partnership now owns 3,174,477 shares of the company’s stock worth $1,207,666,000 after purchasing an additional 346,178 shares during the last quarter. Janus Henderson Group PLC boosted its holdings in argenx by 24.8% in the first quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock worth $872,690,000 after purchasing an additional 439,889 shares during the period. Capital World Investors increased its stake in argenx by 37.0% during the fourth quarter. Capital World Investors now owns 1,961,202 shares of the company’s stock valued at $746,099,000 after purchasing an additional 530,181 shares during the last quarter. Finally, Avoro Capital Advisors LLC raised its holdings in shares of argenx by 0.3% during the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock worth $487,609,000 after purchasing an additional 3,900 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on ARGX. Wedbush boosted their price objective on shares of argenx from $519.00 to $560.00 and gave the company an “outperform” rating in a research report on Friday, July 26th. Deutsche Bank Aktiengesellschaft upgraded argenx from a “hold” rating to a “buy” rating in a research report on Thursday, July 25th. Guggenheim boosted their price objective on argenx from $545.00 to $585.00 and gave the company a “buy” rating in a research report on Friday, July 26th. HC Wainwright increased their target price on argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Finally, Piper Sandler boosted their price target on shares of argenx from $522.00 to $535.00 and gave the company an “overweight” rating in a report on Monday, June 24th. Three research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and a consensus price target of $547.74.

argenx Stock Up 1.3 %

Shares of argenx stock opened at $529.06 on Thursday. The business has a fifty day simple moving average of $508.53 and a 200-day simple moving average of $430.04. argenx SE has a fifty-two week low of $327.73 and a fifty-two week high of $554.74. The firm has a market cap of $31.44 billion, a price-to-earnings ratio of -93.47 and a beta of 0.62.

argenx (NASDAQ:ARGX) last issued its quarterly earnings results on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.89) by $1.34. The company had revenue of $489.43 million during the quarter, compared to the consensus estimate of $436.66 million. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. During the same period in the prior year, the company earned ($1.69) EPS. Analysts anticipate that argenx SE will post -0.37 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.